The impact of this dissolution on the earnings of Daiichi Sankyo of the fiscal year ending March 2009 will be negligible, the company said.
Daiichi Sankyo and Sanofi-Aventis have previously established the joint ventures Laboratoire Daiichi Sanofi-Aventis (LDS) and Sanofi-Aventis Daiichi Pharmaceutical (SDC) with the objective of developing pharmaceuticals for treatment of thrombotic disease.
The dissolution of LDS and SDC was agreed upon by both companies in 2005. With post-dissolution procedures now possible, LDS is to be dissolved on January 13, 2009 and SDC is to be dissolved on December 26, 2008.